Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Metzger

Showing results (351-360 of 415) with videos related to

Pageof 42
Sort By:
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1986
Effects of N-linked carbohydrate on the in vivo properties of human GM-CSFR E Donahue, E A Wang, R J Kaufman, et al.
Brain Research|May 4, 2026
uPAR exhibits age- and region-dependent expression in the brains of mice with Alzheimer's disease-like pathologyLauren E Sarko, Ella Klaus, Viktoriya Bondarenko, et al.
Diabetes & Metabolism|May 1, 2018
Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) StudyB Balkau, M Metzger, F Andreelli, et al.
The Journal of Clinical Investigation|February 13, 2001
In vivo acceleration of heart relaxation performance by parvalbumin gene deliveryM L Szatkowski, M V Westfall, C A Gomez, et al.
Physiological Genomics|March 13, 2008
Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering actionSharlene M Day, Pierre Coutu, Wang Wang, et al.
Pharmacology Research & Perspectives|March 16, 2016
Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic targetWendy Ankrom, Harold B Wood, Jiayi Xu, et al.
Journal of Medicinal Chemistry|April 26, 1996
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Molecular Psychiatry|July 1, 1996
Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigreeL Shihabuddin, J M Silverman, M S Buchsbaum, et al.
Endocrinology|May 19, 2011
Effects of peripherally administered neuromedin U on energy and glucose homeostasisAndrea M Peier, Kunal Desai, James Hubert, et al.
Oral Diseases|April 9, 2010
Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glandsC Zheng, A Voutetakis, M Metzger, et al.
Pageof 42

Showing results (351-360 of 415) with videos related to

Sort By:
Pageof 42
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1986
Effects of N-linked carbohydrate on the in vivo properties of human GM-CSFR E Donahue, E A Wang, R J Kaufman, et al.
Brain Research|May 4, 2026
uPAR exhibits age- and region-dependent expression in the brains of mice with Alzheimer's disease-like pathologyLauren E Sarko, Ella Klaus, Viktoriya Bondarenko, et al.
Diabetes & Metabolism|May 1, 2018
Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) StudyB Balkau, M Metzger, F Andreelli, et al.
The Journal of Clinical Investigation|February 13, 2001
In vivo acceleration of heart relaxation performance by parvalbumin gene deliveryM L Szatkowski, M V Westfall, C A Gomez, et al.
Physiological Genomics|March 13, 2008
Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering actionSharlene M Day, Pierre Coutu, Wang Wang, et al.
Pharmacology Research & Perspectives|March 16, 2016
Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic targetWendy Ankrom, Harold B Wood, Jiayi Xu, et al.
Journal of Medicinal Chemistry|April 26, 1996
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonistJ J Hale, S G Mills, M MacCoss, et al.
Molecular Psychiatry|July 1, 1996
Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigreeL Shihabuddin, J M Silverman, M S Buchsbaum, et al.
Endocrinology|May 19, 2011
Effects of peripherally administered neuromedin U on energy and glucose homeostasisAndrea M Peier, Kunal Desai, James Hubert, et al.
Oral Diseases|April 9, 2010
Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glandsC Zheng, A Voutetakis, M Metzger, et al.
Pageof 42